FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2156920992> ?p ?o ?g. }

• W2156920992 endingPage "1318" @default.
• W2156920992 startingPage "1314" @default.
• W2156920992 abstract "In this study, we examined the efficacy and toxicity of S-1 with cisplatin as a second-line palliative chemotherapy for gemcitabine-refractory pancreatic cancer patients. Patients who had been previously treated with gemcitabine-based chemotherapy as palliative first-line chemotherapy received S-1/cisplatin [body surface area (BSA) <1.25 m2 , S-1 40 mg/day; BSA ≤1.25 to <1.5 m2, 50 mg/day; BSA ≥1.5 m2 60 mg/day, orally, bid, daily on days 1-14 followed by a 7-day washout and cisplatin 60 mg/m2/day intravenously on day 1] every three weeks. The enrollment of 32 patients was planned, but the study was terminated early, prior to the first stage, following the enrollment of 11 patients. The median age of the patients was 56 (range, 42-74) years. Nine patients had a performance status (PS) of one. In total, there were 21 chemotherapy cycles and the median treatment duration was 21 (range, 7-96) days. Of the 11 patients, five could not be evaluated due to discontinuation prior to the response evaluation. One of the six evaluable patients achieved stable disease (9.1% in intention to treat analysis and 16.7% in per-protocol analysis), while five had progressive disease. Grade 3-4 hematological toxicities were anemia in one, neutropenia in one and thrombocytopenia in one cycle. Grade 3-4 nonhematological toxicities were fatigue in three, nausea in four, anorexia in two, diarrhea in one and peripheral neuropathy in two cycles. With a median follow-up period of 8.9 (range, 3.2-11.3) months, the median time to progression was 44 days [95% confidence interval (CI) 25.4-62.6] and the median overall survival was 81 days (95% CI 9.3-152.7). Combination chemotherapy with S-1 and cisplatin as applied in this study did not result in promising antitumor activity, a high degree of toxicity and poor compliance." @default.
• W2156920992 created "2016-06-24" @default.
• W2156920992 creator A5001027928 @default.
• W2156920992 creator A5013400032 @default.
• W2156920992 creator A5023107984 @default.
• W2156920992 creator A5024677686 @default.
• W2156920992 creator A5025416763 @default.
• W2156920992 creator A5029196519 @default.
• W2156920992 creator A5035019823 @default.
• W2156920992 creator A5041723605 @default.
• W2156920992 creator A5044444009 @default.
• W2156920992 creator A5047621773 @default.
• W2156920992 creator A5049025663 @default.
• W2156920992 creator A5069005269 @default.
• W2156920992 creator A5070313719 @default.
• W2156920992 creator A5071881182 @default.
• W2156920992 creator A5072592911 @default.
• W2156920992 creator A5073384154 @default.
• W2156920992 creator A5086526948 @default.
• W2156920992 date "2012-03-08" @default.
• W2156920992 modified "2023-09-27" @default.
• W2156920992 title "Phase II study of palliative S-1 in combination with cisplatin as second-line chemotherapy for gemcitabine-refractory pancreatic cancer patients" @default.
• W2156920992 cites W1931508686 @default.
• W2156920992 cites W2009325232 @default.
• W2156920992 cites W2015326709 @default.
• W2156920992 cites W2024598695 @default.
• W2156920992 cites W2029813189 @default.
• W2156920992 cites W2082243630 @default.
• W2156920992 cites W2087362450 @default.
• W2156920992 cites W2130864695 @default.
• W2156920992 cites W2131972171 @default.
• W2156920992 cites W2139248078 @default.
• W2156920992 cites W2142331799 @default.
• W2156920992 cites W2144263487 @default.
• W2156920992 cites W2145579761 @default.
• W2156920992 cites W2146854383 @default.
• W2156920992 cites W2147546342 @default.
• W2156920992 cites W2151253787 @default.
• W2156920992 cites W2153118978 @default.
• W2156920992 cites W2158734599 @default.
• W2156920992 cites W2171075804 @default.
• W2156920992 cites W2187511042 @default.
• W2156920992 cites W2224480680 @default.
• W2156920992 cites W2226732348 @default.
• W2156920992 cites W2230554281 @default.
• W2156920992 cites W2285738680 @default.
• W2156920992 cites W2409438405 @default.
• W2156920992 cites W2410076741 @default.
• W2156920992 doi "https://doi.org/10.3892/ol.2012.637" @default.
• W2156920992 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3392570" @default.
• W2156920992 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22783441" @default.
• W2156920992 hasPublicationYear "2012" @default.
• W2156920992 type Work @default.
• W2156920992 sameAs 2156920992 @default.
• W2156920992 citedByCount "11" @default.
• W2156920992 countsByYear W21569209922012 @default.
• W2156920992 countsByYear W21569209922013 @default.
• W2156920992 countsByYear W21569209922014 @default.
• W2156920992 countsByYear W21569209922015 @default.
• W2156920992 countsByYear W21569209922016 @default.
• W2156920992 countsByYear W21569209922018 @default.
• W2156920992 countsByYear W21569209922022 @default.
• W2156920992 crossrefType "journal-article" @default.
• W2156920992 hasAuthorship W2156920992A5001027928 @default.
• W2156920992 hasAuthorship W2156920992A5013400032 @default.
• W2156920992 hasAuthorship W2156920992A5023107984 @default.
• W2156920992 hasAuthorship W2156920992A5024677686 @default.
• W2156920992 hasAuthorship W2156920992A5025416763 @default.
• W2156920992 hasAuthorship W2156920992A5029196519 @default.
• W2156920992 hasAuthorship W2156920992A5035019823 @default.
• W2156920992 hasAuthorship W2156920992A5041723605 @default.
• W2156920992 hasAuthorship W2156920992A5044444009 @default.
• W2156920992 hasAuthorship W2156920992A5047621773 @default.
• W2156920992 hasAuthorship W2156920992A5049025663 @default.
• W2156920992 hasAuthorship W2156920992A5069005269 @default.
• W2156920992 hasAuthorship W2156920992A5070313719 @default.
• W2156920992 hasAuthorship W2156920992A5071881182 @default.
• W2156920992 hasAuthorship W2156920992A5072592911 @default.
• W2156920992 hasAuthorship W2156920992A5073384154 @default.
• W2156920992 hasAuthorship W2156920992A5086526948 @default.
• W2156920992 hasBestOaLocation W21569209921 @default.
• W2156920992 hasConcept C121608353 @default.
• W2156920992 hasConcept C126322002 @default.
• W2156920992 hasConcept C141071460 @default.
• W2156920992 hasConcept C143998085 @default.
• W2156920992 hasConcept C2776694085 @default.
• W2156920992 hasConcept C2776907518 @default.
• W2156920992 hasConcept C2777063308 @default.
• W2156920992 hasConcept C2778248108 @default.
• W2156920992 hasConcept C2778715236 @default.
• W2156920992 hasConcept C2778822529 @default.
• W2156920992 hasConcept C2780210213 @default.
• W2156920992 hasConcept C2780258809 @default.
• W2156920992 hasConcept C2780580376 @default.
• W2156920992 hasConcept C71924100 @default.
• W2156920992 hasConcept C90924648 @default.
• W2156920992 hasConceptScore W2156920992C121608353 @default.
• W2156920992 hasConceptScore W2156920992C126322002 @default.

• next